William Blair analyst Lachlan Hanbury-Brown reiterated an Outperform rating on Ocular Therapeutix (NASDAQ: OCUL)The analyst commented, "We believe the additional ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE